Retina/Vitreous News

SEATTLE — The phase 2 PAVIA trial investigating Duravyu, previously known as EYP-1901, for the treatment of nonproliferative diabetic retinopathy did not meet its primary endpoint, according to a press release from EyePoint Pharmaceuticals.

SEATTLE — Funding from the Chronic Disease Foundation impacts the decision to stay on a chosen therapy in patients with age-related macular degeneration, according to a poster presentation.

SEATTLE — In this Healio Video Perspective from the ARVO meeting, Jennifer I. Lim, MD, discusses anti-VEGF therapy for the treatment of proliferative sickle cell retinopathy.

Among individuals with a history of uveitis, COVID-19 vaccination was linked to an increased risk for recurrent uveitis, particularly in the first month after vaccination, according to a study published in JAMA Ophthalmology.

SEATTLE — In this Healio Video Perspective from the ARVO meeting, Ashkan M. Abbey, MD, discusses efficacy and safety data for pegcetacoplan for geographic atrophy treatment at 36 months.

Ramin Tadayoni, MD, PhD, newly elected president of the European Society of Retina Specialists and highly esteemed member of the global retina community, died unexpectedly on April 20.

Women in the vitreoretinal subspecialty experience male-dominated mentorship in training, according to a poster presentation at Real World Ophthalmology.

Lensrxlab, a provider of diabetic, safety and dress eye wear, announced the launch of its supplemental vision benefits platform for diabetics, which offers an all-in-one prescription diabetic eye wear package.

The FDA accepted an investigational new drug application for a trispecific fusion antibody for the treatment of diabetic macular edema, according to a press release from Eluminex Biosciences.

One thousand physicians, health care providers and industry members will gather in Fort Lauderdale, Florida, in May for the Retina World Congress 2024 hosted in conjunction with Healio Live.